<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/8C60EACC-2042-4C1A-B611-814952374BA5"><gtr:id>8C60EACC-2042-4C1A-B611-814952374BA5</gtr:id><gtr:name>Faculty of Medicine, Dentistry and Health</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:department>Molecular Biology and Biotechnology</gtr:department><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8C60EACC-2042-4C1A-B611-814952374BA5"><gtr:id>8C60EACC-2042-4C1A-B611-814952374BA5</gtr:id><gtr:name>Faculty of Medicine, Dentistry and Health</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A21CA907-96DD-49B6-B253-3D7E088746EA"><gtr:id>A21CA907-96DD-49B6-B253-3D7E088746EA</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Peter</gtr:otherNames><gtr:surname>Hornby</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0500364"><gtr:id>CE04FF15-7C36-43DB-9DAC-0F5B37BDC047</gtr:id><gtr:title>Nitric oxide co-ordinates early defence responses through mitochondrial regulation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500364</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Nitric oxide (NO) plays an important role as an inter- and intra-cellular messenger, acting in the cardiovascular system, in the nervous system and as a component of the immune system. NO is a diatomic free radical which is a gas at room temperature, making it highly diffusible within the vasculature. One of its major targets is the soluble guanylyl cyclase (sGC). The binding of NO to Fe2+ in the haem group of sGC activates the enzyme and increases the concentration of cGMP (guanosine 3?, 5?-cyclic monophosphate). For many years we have focused on NO/cGMP signalling and the importance of this pathway to a wide range of biological systems, including blood pressure regulation, platelet aggregation, smooth muscle relaxation and peripheral and central neurotransmission. More recently we have been involved in understanding how NO can signal via a completely different pathway that has equally important pleiotropic biological consequences. We have shown that NO, in the nanomolar concentration range that activates sGC, can also bind to the mitochondrial enzyme cytochrome c oxidase (complex IV) and inhibit it in a manner that is reversible and in competition with oxygen. This inhibition can prevent the enzyme from using any available oxygen, resulting in what we have termed ?metabolic hypoxia?. We aim to further our understanding of how this NO-mediated inhibition of cellular respiration results in signalling to transduction pathways that ultimately control the fate of the cell. In order to do this we have developed a series of biochemical techniques, cell lines and reagents that permit the highly regulated generation of NO in a dose- and time?dependent manner.</gtr:technicalSummary><gtr:fund><gtr:end>2010-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1242801</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bayer</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Targeting GRP78 for cancer diagnosis and treatment</gtr:description><gtr:id>3E548A3C-2895-4F69-9DCC-5E4324A3ABF2</gtr:id><gtr:impact>The collaboration with university of Newcastle has been successful, resulted in a publication in JBC, PMID 16418174. The animal model is running and will produce results soon</gtr:impact><gtr:partnerContribution>Purify functional proteinProfessor Nicola Brown is helping us to develop animal modelDr. Marilena Loizidou is helping us to analyze the breast cancer in situ hybridization results.</gtr:partnerContribution><gtr:piContribution>We have identified that nitric oxide upregulates GRP78 protein through coupling ER stress and mitochondria respiration. As GRP78 is a good target for cancer diagnosis and treatment, we have developed specific antibody. University of Newcastle has provided us recombinant protein. We have carried out screening phage library and isolated antibody has been used to in nude mice animal model(a grant supported by Bayer Healthcare and in situ hybridization for breast cancer detection(Patholgy analysis has been helped by UCL, Division of Surgery.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Newcastle</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cell and Molecular Biosciences</gtr:department><gtr:description>Targeting GRP78 for cancer diagnosis and treatment</gtr:description><gtr:id>7CB02FEF-9BB2-455B-BC87-96487B3AB8B8</gtr:id><gtr:impact>The collaboration with university of Newcastle has been successful, resulted in a publication in JBC, PMID 16418174. The animal model is running and will produce results soon</gtr:impact><gtr:partnerContribution>Purify functional proteinProfessor Nicola Brown is helping us to develop animal modelDr. Marilena Loizidou is helping us to analyze the breast cancer in situ hybridization results.</gtr:partnerContribution><gtr:piContribution>We have identified that nitric oxide upregulates GRP78 protein through coupling ER stress and mitochondria respiration. As GRP78 is a good target for cancer diagnosis and treatment, we have developed specific antibody. University of Newcastle has provided us recombinant protein. We have carried out screening phage library and isolated antibody has been used to in nude mice animal model(a grant supported by Bayer Healthcare and in situ hybridization for breast cancer detection(Patholgy analysis has been helped by UCL, Division of Surgery.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Faculty of Medicine, Dentistry and Health</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Oncology</gtr:department><gtr:description>Targeting GRP78 for cancer diagnosis and treatment</gtr:description><gtr:id>C7604D2A-B601-4054-B8F9-48291F33C203</gtr:id><gtr:impact>The collaboration with university of Newcastle has been successful, resulted in a publication in JBC, PMID 16418174. The animal model is running and will produce results soon</gtr:impact><gtr:partnerContribution>Purify functional proteinProfessor Nicola Brown is helping us to develop animal modelDr. Marilena Loizidou is helping us to analyze the breast cancer in situ hybridization results.</gtr:partnerContribution><gtr:piContribution>We have identified that nitric oxide upregulates GRP78 protein through coupling ER stress and mitochondria respiration. As GRP78 is a good target for cancer diagnosis and treatment, we have developed specific antibody. University of Newcastle has provided us recombinant protein. We have carried out screening phage library and isolated antibody has been used to in nude mice animal model(a grant supported by Bayer Healthcare and in situ hybridization for breast cancer detection(Patholgy analysis has been helped by UCL, Division of Surgery.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Division of Surgery &amp; Interventional Science</gtr:department><gtr:description>Targeting GRP78 for cancer diagnosis and treatment</gtr:description><gtr:id>588FD925-7BC8-4D73-9CA1-968E4B02A2FA</gtr:id><gtr:impact>The collaboration with university of Newcastle has been successful, resulted in a publication in JBC, PMID 16418174. The animal model is running and will produce results soon</gtr:impact><gtr:partnerContribution>Purify functional proteinProfessor Nicola Brown is helping us to develop animal modelDr. Marilena Loizidou is helping us to analyze the breast cancer in situ hybridization results.</gtr:partnerContribution><gtr:piContribution>We have identified that nitric oxide upregulates GRP78 protein through coupling ER stress and mitochondria respiration. As GRP78 is a good target for cancer diagnosis and treatment, we have developed specific antibody. University of Newcastle has provided us recombinant protein. We have carried out screening phage library and isolated antibody has been used to in nude mice animal model(a grant supported by Bayer Healthcare and in situ hybridization for breast cancer detection(Patholgy analysis has been helped by UCL, Division of Surgery.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Technology (MRCT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Develop of novel inhibitors of PCSK9 for treatment of hypercholesterolaemia</gtr:description><gtr:id>72DCC4C0-6208-403A-A072-78D4B63BF2CE</gtr:id><gtr:impact>We have just started to optimizing the HTS screening
conditions and will produce results soon.</gtr:impact><gtr:partnerContribution>The MRCT provide us the NINDS compounds library, a collection of known drugs and pharmcologically activi compounds. The Department provide high-throughput screening facility and experienced HTS expert to help us screening compounds library.</gtr:partnerContribution><gtr:piContribution>Our group has identified a novel pathway to regulate cholesterol uptake by regulating PCSK9 and set up the screening assay. MRC Technology supplied us the NINDS compounds library. The high-throughput screening facility is provided by the Dept of Cardiovascular Science, University of Sheffield</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Faculty of Medicine, Dentistry and Health</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Cardiovascular Science</gtr:department><gtr:description>Develop of novel inhibitors of PCSK9 for treatment of hypercholesterolaemia</gtr:description><gtr:id>BAA4B63D-1692-428A-A554-80CEED5400BB</gtr:id><gtr:impact>We have just started to optimizing the HTS screening
conditions and will produce results soon.</gtr:impact><gtr:partnerContribution>The MRCT provide us the NINDS compounds library, a collection of known drugs and pharmcologically activi compounds. The Department provide high-throughput screening facility and experienced HTS expert to help us screening compounds library.</gtr:partnerContribution><gtr:piContribution>Our group has identified a novel pathway to regulate cholesterol uptake by regulating PCSK9 and set up the screening assay. MRC Technology supplied us the NINDS compounds library. The high-throughput screening facility is provided by the Dept of Cardiovascular Science, University of Sheffield</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>43100</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>From Targets to Novel Drugs</gtr:description><gtr:end>2011-08-02</gtr:end><gtr:fundingOrg>Bayer</gtr:fundingOrg><gtr:id>EB44EAE4-ABED-414C-9594-5A916BE20414</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>we generated a human T-Rex-293 stable cell line that overexpressed FLAG-tagged F216L-PCSK9</gtr:description><gtr:id>F5629D20-5599-44A2-943E-2C365D59B36F</gtr:id><gtr:impact>It is very useful to study mutation form F216L-PCSK9 function and purify protein</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Overexpressed F216L-PCSK9 stable cell line</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We generated a human-T-Rex-293 stable cell line that overexpressed Flag-tagged D374Y mutation.</gtr:description><gtr:id>AA5566D2-559F-452A-9577-BAB87BA3A3F7</gtr:id><gtr:impact>It is very useful for study mutation form D374Y-PCSK9 and purify protein</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Overexpressed D374Y-PCSk9 stable cell line</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>we generated a human T-Rex-293 stable cell line that overexpressed Flag-tagged S127R-PCSK9.</gtr:description><gtr:id>35EE75BA-4B43-4358-9DC5-A2677EDC6FB5</gtr:id><gtr:impact>It is very useful for study mutation form S127R-PCSK9 function and purify protein</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Overexpress S127R-PCSK9 stable cell line</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Specific for GRP78 protein, potentially for caner diagnosis and treatment</gtr:description><gtr:id>7A5BF5F4-C547-4F56-8C2D-5AE952368C3A</gtr:id><gtr:impact>This is a potentially therapeutic humanized antibody fragment, targeting cancer cell surface. It is subjected to ongoing patent application</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>anti-GRP78 scFv antibody</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have generated a human-T-Rex-293 stable cell line that over-expressed Flag-tagged wild-typ PCSK9</gtr:description><gtr:id>EF2D2337-0A75-4C3B-8426-CC7CDCB5040E</gtr:id><gtr:impact>It can be used to study PCSK9 function and purify PCSK9 protein</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Wild-type PCSK9 overexpressing stable cell line</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/447D98BC-16CB-43EC-9844-6B01143287CA"><gtr:id>447D98BC-16CB-43EC-9844-6B01143287CA</gtr:id><gtr:title>c-IAP1 binds and processes PCSK9 protein: linking the c-IAP1 in a TNF-a pathway to PCSK9-mediated LDLR degradation pathway.</gtr:title><gtr:parentPublicationTitle>Molecules (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3e142474496bfae125798f6d29c9477e"><gtr:id>3e142474496bfae125798f6d29c9477e</gtr:id><gtr:otherNames>Xu W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1420-3049</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BE3DBEF1-7B05-49B9-8E45-D343DE4C59E4"><gtr:id>BE3DBEF1-7B05-49B9-8E45-D343DE4C59E4</gtr:id><gtr:title>Quantum dot-conjugated anti-GRP78 scFv inhibits cancer growth in mice.</gtr:title><gtr:parentPublicationTitle>Molecules (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3e142474496bfae125798f6d29c9477e"><gtr:id>3e142474496bfae125798f6d29c9477e</gtr:id><gtr:otherNames>Xu W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1420-3049</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2E44E91C-A770-4EB3-96DB-EF241D262433"><gtr:id>2E44E91C-A770-4EB3-96DB-EF241D262433</gtr:id><gtr:title>The affinity of a major Ca2+ binding site on GRP78 is differentially enhanced by ADP and ATP.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/212fefb641bc6268249bd5366300ad3d"><gtr:id>212fefb641bc6268249bd5366300ad3d</gtr:id><gtr:otherNames>Lamb HK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9575BB6E-F3B3-4B63-B8E8-37E6AD367FE2"><gtr:id>9575BB6E-F3B3-4B63-B8E8-37E6AD367FE2</gtr:id><gtr:title>Targeting Nitric Oxide Mediated Upregulation of Membrane-bound Glucose Regulated-protein 78 by Subtractive Single Chain Variable Fragment (scFv) Phage Display</gtr:title><gtr:parentPublicationTitle>American Journal of Biomedical Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b730bf7815eebc625c914f7f96b885cf"><gtr:id>b730bf7815eebc625c914f7f96b885cf</gtr:id><gtr:otherNames>Liu L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6BB3236A-0A55-4692-87A5-7AF49139CF3A"><gtr:id>6BB3236A-0A55-4692-87A5-7AF49139CF3A</gtr:id><gtr:title>Targeting Cyclooxygenase and Nitric Oxide Pathway Cross-Talk: A New Signal Transduction Pathway for Developing More Effective Anti- Inflammatory Drugs</gtr:title><gtr:parentPublicationTitle>Current Signal Transduction Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b730bf7815eebc625c914f7f96b885cf"><gtr:id>b730bf7815eebc625c914f7f96b885cf</gtr:id><gtr:otherNames>Liu L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500364</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>